Laine said all cox-2 inhibitors carry a risk of
The new trial was done as part of the U.S. Food and Drug Administration's approval process, Laine noted.
Dr. Joost Drenth, of Radboud University Nijmegen Medical Center, the Netherlands, and author of an accompanying editorial in the journal, said there wasn't enough difference between the drugs in terms of gastrointestinal toxicity to show that etoricoxib was better.
"My advice would be to fall back to the good, old, classic
NSAIDs with the addition of a proton pump inhibitor. Because we
know adding a proton pump inhibitor to NSAIDs will decrease the
Another expert thinks etoricoxib and diclofenac are really two similar drugs, because diclofenac acts very much like a cox-2 inhibitor.
"It's not surprising that you don't see much of a difference when you compare Coke and Pepsi," said Dr. James M. Scheiman, a professor of medicine at the University of Michigan Medical Center.
Scheiman thinks the main concern with cox-2 inhibitors is weighing the cardiac risks with the gastrointestinal risks. "Which drug a patient should take is entirely driven by their underlying cardiac and gastrointestinal risk," he said. "Cox-2 inhibitors have a clear advantage on the gastrointestinal side when compared to drugs that aren't cox-2 inhibitors."
Dr. Mark Fendrick, a professor of internal medicine at the
University of Michigan School of Medicine, agreed. "If you have
"If you had a prior
More information
For more information on cox-2 inhibitors, visit the U.S. Food and Drug Administration.




















